Xenon Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
Xenon Pharmaceuticals (XENE) Tops Q3 EPS by 2c
November 10, 2021 4:24 PM ESTXenon Pharmaceuticals (NASDAQ: XENE) reported Q3 EPS of ($0.36), $0.02 better than the analyst estimate of ($0.38). Revenue for the quarter came in at $8.12 million versus the consensus estimate of $10.22 million.
Cash and cash equivalents and marketable securities as of September 30, 2021 were $249.6 million, compared to $177.0 million as of... More
